Compare Jins Holdings, Inc. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 26.92%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 37.65
2
The company has declared Positive results for the last 8 consecutive quarters
3
With ROCE of 46.34%, it has a attractive valuation with a 8.74 Enterprise value to Capital Employed
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 121,818 Million (Small Cap)
27.00
NA
0.00%
-0.09
28.31%
3.83
Revenue and Profits:
Net Sales:
23,987 Million
(Quarterly Results - Nov 2025)
Net Profit:
1,463 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.36%
0%
-31.36%
6 Months
-33.12%
0%
-33.12%
1 Year
-25.04%
0%
-25.04%
2 Years
26.3%
0%
26.3%
3 Years
34.97%
0%
34.97%
4 Years
-23.38%
0%
-23.38%
5 Years
-26.1%
0%
-26.1%
Jins Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.70%
EBIT Growth (5y)
4.46%
EBIT to Interest (avg)
44.88
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
2.36
Tax Ratio
31.40%
Dividend Payout Ratio
30.54%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
29.40%
ROE (avg)
15.81%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
7.15
EV to EBIT
18.85
EV to EBITDA
14.74
EV to Capital Employed
8.74
EV to Sales
2.19
PEG Ratio
0.19
Dividend Yield
NA
ROCE (Latest)
46.34%
ROE (Latest)
26.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : May 2015
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ
Nov'25
Aug'25
Change(%)
Net Sales
23,987.00
27,400.00
-12.46%
Operating Profit (PBDIT) excl Other Income
2,825.00
3,989.00
-29.18%
Interest
44.00
42.00
4.76%
Exceptional Items
-3.00
-636.00
99.53%
Consolidate Net Profit
1,463.00
2,045.00
-28.46%
Operating Profit Margin (Excl OI)
84.40%
116.90%
-3.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Nov 2025 is -12.46% vs 9.67% in Aug 2025
Consolidated Net Profit
QoQ Growth in quarter ended Nov 2025 is -28.46% vs -18.20% in Aug 2025
Annual Results Snapshot (Consolidated) - Aug'25
Aug'25
Aug'24
Change(%)
Net Sales
97,215.00
82,999.00
17.13%
Operating Profit (PBDIT) excl Other Income
15,041.00
10,763.00
39.75%
Interest
155.00
129.00
20.16%
Exceptional Items
-653.00
-773.00
15.52%
Consolidate Net Profit
8,330.00
4,671.00
78.33%
Operating Profit Margin (Excl OI)
124.40%
94.40%
3.00%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2025 is 17.13% vs 13.29% in Aug 2024
Consolidated Net Profit
YoY Growth in year ended Aug 2025 is 78.33% vs 165.10% in Aug 2024
About Jins Holdings, Inc. 
Jins Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






